000108365 001__ 108365
000108365 005__ 20240122154814.0
000108365 0247_ $$2doi$$a10.3389/fendo.2021.748254
000108365 0248_ $$2sideral$$a124960
000108365 037__ $$aART-2021-124960
000108365 041__ $$aeng
000108365 100__ $$0(orcid)0000-0001-5573-6144$$aLayunta, Elena$$uUniversidad de Zaragoza
000108365 245__ $$aCrosstalk between intestinal serotonergic system and pattern recognition receptors on microbiota-gut-brain axis
000108365 260__ $$c2021
000108365 5060_ $$aAccess copy available to the general public$$fUnrestricted
000108365 5203_ $$aDisruption of the microbiota–gut–brain axis results in a wide range of pathologies that are affected, from the brain to the intestine. Gut hormones released by enteroendocrine cells to the gastrointestinal (GI) tract are important signaling molecules within this axis. In the search for the language that allows microbiota to communicate with the gut and the brain, serotonin seems to be the most important mediator. In recent years, serotonin has emerged as a key neurotransmitter in the gut–brain axis because it largely contributes to both GI and brain physiology. In addition, intestinal microbiota are crucial in serotonin signaling, which gives more relevance to the role of the serotonin as an important mediator in microbiota–host interactions. Despite the numerous investigations focused on the gut–brain axis and the pathologies associated, little is known regarding how serotonin can mediate in the microbiota–gut–brain axis. In this review, we will mainly discuss serotonergic system modulation by microbiota as a pathway of communication between intestinal microbes and the body on the microbiota–gut–brain axis, and we explore novel therapeutic approaches for GI diseases and mental disorders.
000108365 536__ $$9info:eu-repo/grantAgreement/ES/DGA/ARAINF-0567-2012$$9info:eu-repo/grantAgreement/ES/DGA/A20-20R
000108365 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000108365 590__ $$a6.055$$b2021
000108365 592__ $$a1.375$$b2021
000108365 594__ $$a6.3$$b2021
000108365 591__ $$aENDOCRINOLOGY & METABOLISM$$b33 / 146 = 0.226$$c2021$$dQ1$$eT1
000108365 593__ $$aEndocrinology, Diabetes and Metabolism$$c2021$$dQ1
000108365 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000108365 700__ $$0(orcid)0000-0002-8467-0356$$aBuey, Berta
000108365 700__ $$0(orcid)0000-0003-4758-3998$$aMesonero, Jose Emilio$$uUniversidad de Zaragoza
000108365 700__ $$0(orcid)0000-0002-5797-3909$$aLatorre, Eva$$uUniversidad de Zaragoza
000108365 7102_ $$11012$$2410$$aUniversidad de Zaragoza$$bDpto. Farmac.Fisiol.y Med.L.F.$$cÁrea Fisiología
000108365 7102_ $$11002$$2050$$aUniversidad de Zaragoza$$bDpto. Bioq.Biolog.Mol. Celular$$cÁrea Biología Celular
000108365 773__ $$g12 (2021), 748254 [24pp.]$$pFront. endocrinol.$$tFrontiers in Endocrinology$$x1664-2392
000108365 8564_ $$s2439798$$uhttps://zaguan.unizar.es/record/108365/files/texto_completo.pdf$$yVersión publicada
000108365 8564_ $$s2268546$$uhttps://zaguan.unizar.es/record/108365/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000108365 909CO $$ooai:zaguan.unizar.es:108365$$particulos$$pdriver
000108365 951__ $$a2024-01-22-15:35:37
000108365 980__ $$aARTICLE